Women’s Health Dx
Sera Prognostics to Present at Baird’s 2020 Global Health Care Conference
September 9, 2020- Sera will be presenting at the upcoming Baird 2020 Global Health Care Conference. A virtual conference, Sera’s presentation will take place on Thursday, September 10 at 10:50 a.m. ET. Read More >
Sera Prognostics Appoints Thomas J. Garite, M.D. as Vice President of Clinical Sciences
June 24, 2020 - Sera announced the appointment Thomas J. Garite, M.D. as Vice President of Clinical Sciences. - Dr. Garite will support clinical development and operations as Sera transitions from clinical to commercial-stage company. Read More >
Publication Demonstrates Ability of Sera Prognostics’ PreTRM® Biomarker Test as a Predictor of Adverse Pregnancy Outcomes
May 20, 2020 - Sera Prognostics, Inc., The Pregnancy Company® announced the publication of positive data in a large, independent, contemporary prospective U.S. clinical cohort study, TREETOP (NCT02787213), in the American Journal of Obstetrics & Gynecology Maternal Fetal Medicine. Read More >
WHO WE ARE
PROVIDING INDIVIDUALIZED RISK ASSESSMENT TO PREDICT AND MANAGE PREMATURE BIRTH, PREECLAMPSIA, AND OTHER PREGNANCY COMPLICATIONS
Sera Prognostics is dedicated to improve the lives of women and babies through individualized prenatal care. Sera’s strategy is to deliver pivotal information to physicians to improve health and to improve the economics of healthcare delivery for pregnant women. Our first test, the PreTRM® Test, focuses on the early prediction of preterm birth risk, one of the most serious pregnancy complications which affects almost one in ten pregnancies in the U.S. alone.
Early and accurate prediction of risk for pregnancy complications helps pregnant women and their doctors better understand risks and proactively address risks of adverse pregnancy outcomes. Learn about the PreTRM® Test for Risk Management.